Establishment and characterization of patient tumor-derived head and neck squamous cell carcinoma xenografts

Cancer Biology and Therapy

Volumn 8, Issue 23, 2009, Pages 2273-2281

  Seshadri, Mukund ^a   Merzianu, Mihai ^a   Tang, Haikuo ^a   Rigual, Nestor R ^a   Sullivan, Maureen ^a   Loree, Thom R ^a   Popat, Saurin R ^a   Repasky, Elizabeth A ^a   Hylander, Bonnie L ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Head and neck cancers; Histopathology; Magnetic resonance imaging; Patient tumor xenografts; Squamous cell carcinoma

Indexed keywords

CD31 ANTIGEN; GADOLINIUM PENTETATE ALBUMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; HEAD AND NECK CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KERATINIZATION; LARYNX TUMOR; MOUSE; MOUTH TUMOR; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; SQUAMOUS CELL CARCINOMA; TONGUE TUMOR; TUMOR GROWTH; XENOGRAFT;

EID: 73949138987     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.23.10137     Document Type: Article

References (34)

1. Davies L, Welch HG. Epidemiology of head and neck cancer in the United States. Otolaryngol Head Neck Surg 2006; 135:451-7.
2. Conley BA. Treatment of advanced head and neck cancer: what lessons have we learned? J Clin Oncol 2006; 24:1023-5.
3. Fidler IJ. Orthotopic implantation of human colon carcinomas into nude mice provides a valuable model for the biology and therapy of metastasis. Cancer Metastasis Rev 1991; 10:229-43.
4. Fu XY, Besterman JM, Monosov A, Hoffman RM. Models of human metastatic colon cancer in nude mice orthotopically constructed by using histologically intact patient specimens. Proc Natl Acad Sci USA 1991; 88:9345-9.
5. Hollingshead MG. Antitumor efficacy testing in rodents. J Natl Cancer Inst 2008; 100:1500-10.
6. Kinders RJ, Hollingshead M, Khin S, Rubinstein L, Tomaszewski JE, Doroshow JH, et al. Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts. Clin Cancer Res 2008; 14:6877-85.
7. Cutz JC, Guan J, Bayani J, Yoshimoto M, Xue H, Sutcliffe M, et al. Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes. Clin Cancer Res 2006; 12:4043-54.
8. Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de Cremoux P, et al. A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 2007; 13:3989-98.
9. Demsar F, Roberts TP, Schwickert HC, Shames DM, van Dijke CF, Mann JS, et al. A MRI spatial mapping technique for microvascular permeability and tissue blood volume based on macromolecular contrast agent distribution. Magn Reson Med 1997; 37:236-42.
10. Turetschek K, Preda A, Novikov V, Brasch RC, Weinmann HJ, Wunderbaldinger P, et al. Tumor microvascular changes in antiangiogenic treatment: assessment by magnetic resonance contrast media of different molecular weights. J Magn Reson Imaging 2004; 20:138-44.
11. Seshadri M, Mazurchuk R, Spernyak JA, Bhattacharya A, Rustum YM, Bellnier DA. Activity of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid against human head and neck carcinoma xenografts. Neoplasia 2006; 8:534-42.
12. Naka T, Sugamura K, Hylander BL, Widmer MB, Rustum YM, Repasky EA. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res 2002; 62:5800-6.
13. Hylander BL, Pitoniak R, Penetrante RB, Gibbs JF, Oktay D, Cheng J, et al. The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice. J Transl Med 2005; 3:22.
14. Chen JC, Shuler CF, Zhang CX, Schuller DE, Milo GE. Histopathologic comparison between human oral squamous cell carcinomas and their xenografts in nude mice. Oral Surg Oral Med Oral Pathol 1991; 71:457-63.
15. Tilgen W, Boukamp P, Breitkreutz D, Dzarlieva RT, Engstner M, Haag D, et al. Preservation of morphological, functional and karyotypic traits during longterm culture and in vivo passage of two human skin squamous cell carcinomas. Cancer Res 1983; 43:5995-6011.
16. Wennerberg J, Willén R, Biörklund A, Tropé C. Histopathological characteristics predictive for growth of squamous cell carcinomas of the head and neck heterotransplanted to nude mice. Anticancer Res 1986; 6:1165-70.
17. Braakhuis BJ, Sneeuwloper G, Snow GB. The potential of the nude mouse xenograft model for the study of head and neck cancer. Arch Otorhinolaryngol 1984; 239:69-79.
18. Robbins KT, Rosenberg W, Weiss B, Varki NM. Growth characteristics of human laryngeal carcinoma in athymic mice. J Otolaryngol 1991; 20:117-22.
19. Lauk S, Zietman A, Skates S, Fabian R, Suit HD. Comparative morphometric study of tumor vasculature in human squamous cell carcinomas and their xenotransplants in athymic nude mice. Cancer Res 1989; 49:4557-61.
20. Le QT, Kong C, Lavori PW, O'byrne K, Erler JT, Huang X, et al. Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2007; 69:167-75.
21. Kaanders JH, Wijffels KI, Marres HA, Ljungkvist AS, Pop LA, van den Hoogen FJ, et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 2002; 62:7066-74.
22. Galmarini FC, Galmarini CM, Sarchi MI, Abulafia J, Galmirini D. Heterogeneous distribution of tumor blood supply affects the response to chemotherapy in patients with head and neck cancer. Microcirculation 2000; 7:405-10.
23. Kyzas PA, Stefanou D, Batistatou A, Agnantis NJ. Prognostic significance of VEGF immunohistochemical expression and tumor angiogenesis in head and neck squamous cell carcinoma. J Cancer Res Clin Oncol 2005; 131:624-30.
24. Laitakari J, Näyhä V, Stenbäck F. Size, shape, structure and direction of angiogenesis in laryngeal tumour development. J Clin Pathol 2004; 57:394-401.
25. Beatrice F, Cammarota R, Giordano C, Corrado S, Ragona R, Sartoris A, et al. Angiogenesis: prognostic significance in laryngeal cancer. Anticancer Res 1998; 18:4737-40.
26. Hasina R, Whipple ME, Martin LE, Kuo WP, Ohno-Machado L, Lingen MW. Angiogenic heterogeneity in head and neck squamous cell carcinoma: biological and therapeutic implications. Lab Invest 2008; 88:342-53.
27. + microvessel density in HNSCC. Oral Oncol 2005; 41:147-55.
28. Lentsch EJ, Goudy S, Sosnowski J, Major S, Bumpous JM. Microvessel density in head and neck squamous cell carcinoma primary tumors and its correlation with clinical staging parameters. Laryngoscope 2006; 116:397-400.
29. Padhani AR. Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions. J Magn Reson Imaging 2002; 16:407-22.
30. Hoskin PJ, Saunders MI, Goodchild K, Powell ME, Taylor NJ, Baddeley H. Dynamic contrast enhanced magnetic resonance scanning as a predictor of response to accelerated radiotherapy for advanced head and neck cancer. Br J Radiol 1999; 72:1093-8.
31. Van Cann EM, Rijpkema M, Heerschap A, van der Bilt A, Koole R, Stoelinga PJ. Quantitative dynamic contrast-enhanced MRI for the assessment of mandibular invasion by squamous cell carcinoma. Oral Oncol 2008; 44:1147-54.
32. Bisdas S, Nguyen SA, Anand SK, Glavina G, Day T, Rumboldt Z. Outcome prediction after surgery and chemoradiation of squamous cell carcinoma in the oral cavity, oropharynx and hypopharynx: use of baseline perfusion CT microcirculatory parameters vs. tumor volume. Int J Radiat Oncol Biol Phys 2009; 73:1313-8.
33. Fu X, Guadagni F, Hoffman RM. A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens. Proc Natl Acad Sci USA 1992; 89:5645-9.
34. Lehr HA, Skelly M, Buhler K, Anderson B, Delisser HM, Gown AM. Microvascular endothelium of human tumor xenografts expresses mouse (=host) CD31. Int J Microcirc Clin Exp 1997; 17:138-42.